Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243371 · ClinicalTrials.gov registry record · Phase 2
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
A Phase 2 study of Previously Treated Metastatic Adenocarcinoma of the Pancreas, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 5
- Study locations
NCT02243371 is a Phase 2 study of Previously Treated Metastatic Adenocarcinoma of the Pancreas that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 93 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT02243371, a Phase 2 study of Previously Treated Metastatic Adenocarcinoma of the Pancreas, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of this study is to compare the overall survival (OS) of subjects with previously treated metastatic pancreatic cancer treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B).
Conditions Studied
Interventions
- DRUG nivolumab
- DRUG CY
- BIOLOGICAL CRS-207
- BIOLOGICAL GVAX
Study Locations (5)
California
- University of California, San Francisco - San Francisco
- Stanford University - Stanford
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Oregon
- Providence Portland Medical Center - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2015-01-02 |
| Est. Completion | 2017-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02243371
The ClinicalTrials.gov registry entry for NCT02243371 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Previously Treated Metastatic Adenocarcinoma of the Pancreas appearing as the primary indexed condition, and to 4 interventions - of which nivolumab is the first listed.
NCT02243371 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Maryland, Oregon.
Frequently Asked Questions
What is clinical trial NCT02243371 about?
NCT02243371 is a clinical study titled "GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab". The primary objective of this study is to compare the overall survival (OS) of subjects with previously treated metastatic pancreatic cancer treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects treated with CY/GVAX pancreas vaccine foll...
What is the current status of trial NCT02243371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2015-01-02. Estimated completion is 2017-07-21.
What conditions does trial NCT02243371 study?
This clinical trial studies the following conditions: Previously Treated Metastatic Adenocarcinoma of the Pancreas.
What interventions are being tested in trial NCT02243371?
The interventions under investigation include: nivolumab (DRUG), CY (DRUG), CRS-207 (BIOLOGICAL), GVAX (BIOLOGICAL).
Who is sponsoring clinical trial NCT02243371?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02243371 being conducted?
This trial has 5 study locations across California, Maryland, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.